Compare Quest Diagnostics Inc (DGX) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Nuscale Power Corporation — how do they compare? Quest Diagnostics Inc trades at $205.15 (market cap $22.80B), while Nuscale Power Corporation trades at $8.14 (market cap $2.98B). The key difference: Quest Diagnostics Inc is far larger — about 7.7× Nuscale Power Corporation's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| DGX | SMR | |
|---|---|---|
Market Cap | $22.80B | $2.98B |
Sector | Health | Utilities |
52-Week High | $216.02 | $53.43 |
52-Week Low | $166.42 | $8.36 |
Enterprise Value | $28.82B | $2.09B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
NuScale Power (SMR) trades at $8.36, down 7.42% in the last session and near its 52-week low. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal significant challenges including negative net income margins (-2,066.55%) and declining revenue projections. Recent news highlights the company's unique position as the only US company with certified small modular reactor design approval, though commercialization timelines remain uncertain.
Despite analyst consensus pointing to 46% upside potential with a $12.25 price target, SMR faces substantial execution risks. The company must demonstrate commercial viability of its reactor technology while managing cash burn. Long-term potential exists in nuclear energy's AI-driven demand surge, but near-term profitability remains elusive with projected losses through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
